Cargando…

S19. THE ROLE OF ACE AS POSSIBLE BIOMARKER FOR TREATMENT RESISTANCE TO ANTIPSYCHOTICS IN FIRST EPISODE OF PSYCHOSIS

BACKGROUND: Angiotensin I–converting enzyme (ACE) is a peptidase that converts angiotensin I into the vasoactive and aldosterone-stimulating peptide angiotensin II, a key protein in controlling blood pressure. Recently, several evidences have shown a role of ACE in psychosis. However, the role of AC...

Descripción completa

Detalles Bibliográficos
Autores principales:	Luisa, Longo, Sawa, Akira
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session I
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7234171/ http://dx.doi.org/10.1093/schbul/sbaa031.085

Ejemplares similares

S122. TEN-YEAR FOLLOW-UP AFTER FIRST EPISODE PSYCHOSIS: FOCUSED ON LOW DOSE ANTIPSYCHOTIC MAINTENANCE AND FUNCTIONING
por: Liu, Chen-Chung, et al.
Publicado: (2020)

S34. EFFECTIVENESS OF INDIVIDUAL METACOGNITIVE TRAINING (MCT+) IN FIRST-EPISODE PSYCHOSIS
por: Ochoa, Susana, et al.
Publicado: (2020)

S166. EFFECTIVE CONNECTIVITY OF FRONTOSTRIATAL SYSTEMS IN FIRST-EPISODE PSYCHOSIS
por: Sabaroedin, Kristina, et al.
Publicado: (2020)

S150. EMOTIONAL BEHAVIOUR IN HIGH-RISK AND FIRST-EPISODE PSYCHOSIS
por: Falkenberg, Irina, et al.
Publicado: (2020)

S163. GLUTAMATERGIC METABOLITES IN THE PSYCHOSIS SPECTRUM: FROM HIGH RISK SAMPLES TO FIRST EPISODE PSYCHOSIS
por: Fortea, Adriana, et al.
Publicado: (2020)

S70. PROFILES OF SOCIAL COGNITION AND METACOGNITION IN FIRST-EPISODE PSYCHOSIS: A LATENT PROFILE ANALYSIS
por: Ferrer-Quintero, Marta, et al.
Publicado: (2020)

S10. SCREENING FOR ANTI-NMDAR ANTIBODIES AMONGST PATIENTS WITH FIRST EPISODE PSYCHOSIS
por: Herman, Levente, et al.
Publicado: (2020)

S25. FRAMEWORK FOR THE CHARACTERIZATION OF HIPPOCAMPUS USING RADIOMIC APPROACH IN FIRST-EPISODE PSYCHOSIS
por: Masias, Mireia, et al.
Publicado: (2020)

S186. THE EFFECTS OF CHILDHOOD TRAUMA ON HIPPOCAMPAL VOLUME IN FIRST EPISODE PSYCHOSIS: DOES CORTISOL PLAY A ROLE?
por: Ciufolini, Simone, et al.
Publicado: (2020)

S79. REINFORCEMENT LEARNING ABNORMALITIES IN INDIVIDUALS AT CLINICAL HIGH RISK AND IN THE FIRST EPISODE OF PSYCHOSIS
por: Datta, Raktima, et al.
Publicado: (2020)

S228. SOCIAL AND OCCUPATIONAL FUNCTIONING AND SATISFACTION WITH CARE IN FINNISH FIRST-EPISODE PSYCHOSIS PATIENTS
por: Barrientos, Paula, et al.
Publicado: (2020)

S232. ASSOCIATIONS OF FOOD CRAVING WITH PSYCHOLOGICAL AND PHYSICAL CHARACTERISTICS IN PATIENTS WITH FIRST-EPISODE PSYCHOSIS
por: Kim, Yeonghyeok, et al.
Publicado: (2020)

S132. SAMPLING BIAS IN STUDIES OF FIRST-EPISODE PSYCHOSIS – A FOLLOW-UP STUDY
por: Walta, Maija, et al.
Publicado: (2020)

S102. DIAGNOSTIC CHALLENGES AT TIME OF INPATIENT ADMISSION: DIAGNOSTIC SHIFTS IN PATIENTS WITH FIRST EPISODE PSYCHOSIS
por: Koch, Marlene, et al.
Publicado: (2020)

S137. LEFT HEMISPHERE MEG DEFICIT IN PITCH AND DURATION MISMATCH NEGATIVITY IN FIRST EPISODE PSYCHOSIS
por: Duricy, Erin, et al.
Publicado: (2020)

S46. IMPAIRED ERROR-PROCESSING IN PATIENTS WITH FIRST-EPISODE PSYCHOSIS: AN EVENT-RELATED POTENTIAL STUDY
por: Park, Jihye, et al.
Publicado: (2020)

S129. REHOSPITALIZATION RATE IN PEOPLE WITH FIRST-EPISODE PSYCHOSIS IN THE CZECH REPUBLIC: A REGISTER-BASED STUDY
por: Kondrátová, Lucie, et al.
Publicado: (2020)

S18. STRUCTURAL COVARIANCE PREDICTORS OF CLINICAL IMPROVEMENT AT 2-YEAR FOLLOW-UP IN FIRST-EPISODE PSYCHOSIS
por: Saiz-Masvidal, Cristina, et al.
Publicado: (2020)

S224. TREATMENT IN THE PSYCHOSIS FIRST EPISODE PROGRAM “ZüRCHER ERSTPSYCHOSEN NETZWERK (ZEN)”: QUALITY CONTROL OF THE OUTCOME
por: Metzler, Sibylle, et al.
Publicado: (2020)

S115. EVALUATION OF THE CLINICAL UTILITY OF SYMPTOM DIMENSIONS ON LONG-TERM CLINICAL AND FUNCTIONAL OUTCOMES IN FIRST EPISODE PSYCHOSIS
por: Bor, Ege, et al.
Publicado: (2020)

S72. MCCB COGNITIVE PROFILE IN CHINESE FIRST EPISODE SCHIZOPHRENIA PATIENTS AND SUBJECTS AT CLINICAL HIGH RISK FOR PSYCHOSIS
por: Lei, Zhao, et al.
Publicado: (2020)

S107. RANDOMIZED CONTROL TRIAL OF A MOBILE APP-BASED INTERVENTION FOR ADOLESCENTS WITH FIRST-EPISODE PSYCHOSIS: THE THINK APP
por: Calvo, Ana, et al.
Publicado: (2020)

S124. EXAMINING THE CLINICAL AND NEUROCOGNITIVE CHARACTERISTICS OF FIRST-EPISODE PSYCHOSIS PATIENTS WHO WILL NEVER RELAPSE OVER 10 YEARS
Publicado: (2020)

S101. DIFFERENTIATING NON-AFFECTIVE ACUTE REMITTING PSYCHOSIS (NARP) FROM SCHIZOPHRENIA IN FIRST-EPISODE PSYCHOSIS: FINDINGS FROM A 3-YEAR LONGITUDINAL STUDY IN THE PAFIP COHORT
por: López-Díaz, Álvaro, et al.
Publicado: (2020)

S96. EXAMINING DIFFERENCES BETWEEN CURRENT CANNABIS CONSUMPTION AND COGNITIVE FUNCTIONING OF FIRST-EPISODE PSYCHOSIS PATIENTS: A RETROSPECTIVE STUDY
por: Pochiet, Gabrielle, et al.
Publicado: (2020)

S95. DIFFERENCES IN LIFETIME PATTERNS OF PSYCHOSTIMULANTS AND THEIR IMPACT ON THE PROPORTION OF PATIENTS WITH FIRST-EPISODE PSYCHOSIS ATTRIBUTABLE TO PSYCHOSTIMULANTS USE ACROSS EUROPE
por: Duran-Cutilla, Manuel, et al.
Publicado: (2020)

S6. SLEEP ENDOPHENOTYPES OF SCHIZOPHRENIA: A HIGH-DENSITY EEG STUDY IN DRUG-NAïVE, FIRST EPISODE PSYCHOSIS PATIENTS
por: Castelnovo, Anna, et al.
Publicado: (2020)

T40. GLYCERYL TRINITRATE IN FIRST EPISODE PSYCHOSIS UNMEDICATED WITH ANTIPSYCHOTICS: A RANDOMISED CONTROLLED FEASIBILITY STUDY
por: Merritt, Kate, et al.
Publicado: (2020)

T154. WHITE MATTER INTEGRITY, DURATION OF UNTREATED PSYCHOSIS, AND ANTIPSYCHOTIC TREATMENT RESPONSE IN MEDICATION-NAïVE FIRST EPISODE PSYCHOSIS PATIENTS
por: Kraguljac, Nina, et al.
Publicado: (2020)

M169. HIPPOCAMPAL GLUTAMATE AND HIPPOCAMPUS SUBFIELD VOLUMES IN ANTIPSYCHOTIC-NAIVE FIRST EPISODE PSYCHOSIS SUBJECTS AND RELATIONSHIPS TO DURATION OF UNTREATED PSYCHOSIS
Publicado: (2020)

S77. ROLE OF DOPAMINE AND GLUTAMATE TRANSPORTERS IN GENERATION OF ANTIPSYCHOTIC EFFICACY
por: Kruyer, Anna, et al.
Publicado: (2020)

T14. HYPOTHALAMIC-PITUITARY-GONADAL AXIS HORMONES IN ANTIPSYCHOTIC NAïVE FIRST-EPISODE OF PSYCHOSIS AND HEALTHY CONTROLS
por: Teresa Pons-Cabrera, Maria, et al.
Publicado: (2020)

S2. ANTIPSYCHOTICS RESULT IN WEIGHT GAIN BUT THE SEVERITY OF WEIGHT GAIN DIFFERS BETWEEN ANTIPSYCHOTICS
por: Bak, Maarten, et al.
Publicado: (2020)

S47. A MULTICENTER STUDY OF COGNITIVE RESERVE IN FIRST-EPISODE PYCHOSIS
por: Amoretti, Silvia, et al.
Publicado: (2020)

S229. THE EFFECT OF FAMILY ENVIRONMENT ON LONGITUDINAL FUNCTIONING IN FIRST PSYCHOTIC EPISODES
por: Verdolini, Norma, et al.
Publicado: (2020)

S236. QUALITY OF LIFE AND ASSOCIATION WITH SYMPTOMS IN PATIENTS WITH SCHIZOPHRENIA SIX YEARS AFTER FIRST EPISODE PSYCHOSES
por: Andersen, Gitte, et al.
Publicado: (2020)

S171. EFFECT OF DAOA GENETIC VARIATION ON WHITE MATTER ALTERATION IN CORPUS CALLOSUM IN PATIENTS WITH FIRST-EPISODE SCHIZOPHRENIA
por: Su, Wenjun, et al.
Publicado: (2020)

S100. INCORRECT DIAGNOSIS OF FIRST EPISODE SCHIZOPHRENIA: IMPACT OF ANXIETY AND THOUGHT DISORDER, AND THE VALUE OF A CONSULTATION CLINIC
Publicado: (2020)

T119. NO DIFFERENCE BETWEEN VOLITIVE AND EXPRESSIVE NEGATIVE SYMPTOMS FOR EARLY TREATMENT RESPONSE IN FIRST EPISODE OF PSYCHOSIS ANTIPSYCHOTIC NAïVE PATIENTS
por: Haguiara, Bernardo, et al.
Publicado: (2020)

S204. REDUCTION OF ANTIPSYCHOTIC DOSES AND POLYPHARMACY: TWO COCHRANE REVIEWS
por: Leucht, Stefan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7qg42ol34grf1ev580cn5u5ap1